VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen Adjuvant arthritis DNA vaccine pCMV3.65 encoding HSP65
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004410
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Rat
  • Collagen type II gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3 expressed chicken type II collagen (CCOL2A1) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA3 (Song et al., 2009)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004407
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Rat
  • hsp65 gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3 expressed mycobacterial heat shock protein 65 (hsp65) (Ragno et al., 1997).
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA3 (Ragno et al., 1997)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: CD4+CD25+Treg cells play a role in restraining auto-aggressive T cells in experimental settings, and 200 μg/kg of pcDNA-CCOL2A1vaccine increased the proportion of CD4+CD25+Treg cells in the blood of arthritic rats compared with those in all other groups (Song et al., 2009).
  • Efficacy: Comparison of all treated and control groups demonstrated clearly that 200 μg/kg of pcDNA-CCOL2A1 vaccine alone in a single intravenous treatment significantly reduced the severity of disease, footpad swelling, arthritic incidence, clinical scores, and deferred the onset of disease (Song et al., 2009).
  • Host IgG (partial) response
    • Description: pcDNA-CCOL2A1 vaccine significantly reduced the levels of serum anti-CII IgG antibodies compared to the negative control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host Il10 from Rattus norvegicus response
    • Description: Concentrations of the Th2-cytokine IL-10 in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host TGF-B from Rattus norvegicus response
    • Description: Concentrations of the Th3-cytokine TGF-β in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host TNF-alpha from Rattus norvegicus response
    • Description: Concentrations of the Th1-cytokine TNF-α in both 200 μg/kg of pcDNA-CCOL2A1 vaccine and MTX groups were significantly lower than those in the negative control and other treatment groups (P < 0.05). Of note, the level of TNF-α in 200 μg/kg of pcDNA-CCOL2A1 vaccine group recovered to that of the normal group (Song et al., 2009).
    • Detailed Gene Information: Click Here.

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Rats treated with pCMV3.65 showed a significantly elevated antibody levels (median 0.707) when compared with vector-treated rats (median 0.351; P < 0.01) and with naive animals (median 0.0715; P < 0.01). Similarly, spleen cells from pCMV3.65-treated rats exhibited significantly higher proliferative responses against the mycobacterial recombinant antigen when compared with vector treated animals (P < 0.05) or with naive rats (P < 0.01) (Ragno et al., 1997).
  • Efficacy: The pCMV3.65-treated rats were significantly protected from disease development in comparison with the control groups injected with the empty plasmid (Ragno et al., 1997).
References References
Song et al., 2009: Song X, Liang F, Liu N, Luo Y, Xue H, Yuan F, Tan L, Sun Y, Xi C, Xi Y. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine. 2009; 27(5); 690-700. [PubMed: 19095031].
Ragno et al., 1997: Ragno S, Colston MJ, Lowrie DB, Winrow VR, Blake DR, Tascon R. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis and rheumatism. 1997; 40(2); 277-283. [PubMed: 9041939].